Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:EFA NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEFAiShares MSCI EAFE ETF$104.33+0.4%$103.72$86.74▼$105.94$77.56B0.7819.15 million shs8.29 million shsNVSNovartis$154.06-0.4%$150.86$112.34▼$170.46$295.04B0.452.05 million shs1.17 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEFAiShares MSCI EAFE ETF+0.54%-0.43%+0.99%+1.70%+15.63%NVSNovartis-0.38%-3.21%+3.70%+0.50%+25.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEFAiShares MSCI EAFE ETF$104.33+0.4%$103.72$86.74▼$105.94$77.56B0.7819.15 million shs8.29 million shsNVSNovartis$154.06-0.4%$150.86$112.34▼$170.46$295.04B0.452.05 million shs1.17 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEFAiShares MSCI EAFE ETF+0.54%-0.43%+0.99%+1.70%+15.63%NVSNovartis-0.38%-3.21%+3.70%+0.50%+25.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEFAiShares MSCI EAFE ETF 0.00N/AN/AN/ANVSNovartis 2.31Hold$141.20-8.35% DownsideCurrent Analyst Ratings BreakdownLatest NVS and EFA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEFAiShares MSCI EAFE ETFN/AN/AN/AN/AN/AN/ANVSNovartis$54.53B5.39$10.70 per share14.40$22.04 per share6.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEFAiShares MSCI EAFE ETFN/AN/A16.48N/AN/AN/AN/AN/AN/ANVSNovartis$13.98B$6.9822.0715.832.6624.87%38.82%15.16%7/21/2026 (Estimated)Latest NVS and EFA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/21/2026Q2 2026NVSNovartis$2.18N/AN/AN/A$14.17 billionN/A4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEFAiShares MSCI EAFE ETF$3.363.22%N/AN/AN/ANVSNovartis$3.082.00%+5.28%44.13%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEFAiShares MSCI EAFE ETFN/AN/AN/ANVSNovartis0.960.850.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEFAiShares MSCI EAFE ETF79.80%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipEFAiShares MSCI EAFE ETFN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEFAiShares MSCI EAFE ETFN/A743.40 millionN/ANot OptionableNVSNovartis75,2671.91 billion1.91 billionOptionableNVS and EFA HeadlinesRecent News About These CompaniesEquitable Trust Co. Has $3 Million Position in Novartis AG $NVSJuly 10 at 4:23 AM | marketbeat.comNovartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?July 9 at 12:12 PM | fool.comPersonal CFO Solutions LLC Acquires 8,720 Shares of Novartis AG $NVSJuly 9 at 6:24 AM | marketbeat.comWhy Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite?July 7 at 3:34 PM | kalkinemedia.comKNovartis' Pipeline Building Continues, Pelacarsen Readout Coming SoonJuly 7 at 8:40 AM | seekingalpha.comNovartis to Expand Oncology Pipeline With Myricx Bio AcquisitionJuly 6, 2026 | zacks.comNovartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug DealJuly 6, 2026 | finance.yahoo.comWhy Novartis (NVS) Stock Fell TodayJuly 6, 2026 | quiverquant.comQNovartis to Buy Myricx Bio for Up to $1.5 BillionJuly 6, 2026 | wsj.comNovartis to acquire UK-based Myricx Bio for up to $1.5 billionJuly 6, 2026 | reuters.comNovartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 CatalystsJuly 4, 2026 | seekingalpha.comNovartis gene therapy Itvisma approved in EU for spinal muscular atrophyJuly 2, 2026 | msn.comNVS Gains EC Approval for SMA Therapy Itvisma in Broad PopulationJuly 2, 2026 | zacks.com3 European Stocks to Carry Investors Through the Back Half of 2026 (NVS)...July 1, 2026 | marketbeat.comNovartis AG (NYSE:NVS) Given Consensus Rating of "Hold" by BrokeragesJune 29, 2026 | americanbankingnews.comNovartis and Antares to develop cancer drugs in a deal worth up to $1.9BJune 25, 2026 | msn.comNovartis Plays Long Game With Antares Deal - Meaning Near-Term Upside UnlikelyJune 25, 2026 | seekingalpha.comAntares Therapeutics signs potential $1.9 billion cancer drug deal with NovartisJune 24, 2026 | reuters.comBiotech's Silent Resurgence (5-Year Base Breakout)June 23, 2026 | zacks.comNovartis AG (NVS) states Rare Muscle Disease Drug Shows Promise in Early TrialJune 23, 2026 | insidermonkey.comNovartis AG (NVS): 7 Best Longevity and Anti-Aging Stocks to BuyJune 22, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS and EFA Company DescriptionsiShares MSCI EAFE ETF NYSEARCA:EFA$104.33 +0.41 (+0.39%) As of 04:10 PM EasterniShares MSCI EAFE ETF, formerly iShares MSCI EAFE Index Fund (the Fund), is an exchange-traded fund. The Fund's investment objective is to seek investment results that correspond to the price and yield performance of its underlying index, MSCI EAFE Index (the Index). The Index has been developed by MSCI Inc. as an equity benchmark for its international stock performance. The Index includes stocks from Europe, Australasia and the Far East. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.Novartis NYSE:NVS$154.06 -0.56 (-0.36%) Closing price 03:59 PM EasternExtended Trading$154.04 -0.02 (-0.01%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab’s Stock Drop Comes With a Bullish Twist Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth PepsiCo’s Dividend Could Turn Patience Into Real Profit Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
